Generation of p53 Suppressor Peptide from the Fragment of p53 Protein

Somatic Cell and Molecular Genetics

Volumn 25, Issue 3, 1999, Pages 115-128

  Mittelman, Jillene M ^a   Gudkov, Andrei V ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNIDENTIFIED RETROVIRUS;

CARRIER PROTEIN; HYBRID PROTEIN; PENETRATIN; PEPTIDE FRAGMENT; PROTEIN P53;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; DRUG EFFECT; GENE REPRESSION; GENETICS; HUMAN; METABOLISM; MOUSE; TRANSACTIVATION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; APOPTOSIS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; HUMANS; MICE; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; SUPPRESSION, GENETIC; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033123425     PISSN: 07407750     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018822121890     Document Type: Article

References (30)

1. Gottlieb, T.M., and Oren, M. (1996). p53 in growth control and neoplasia. Biochim. Biophys. Acta. 1287:77-102.
2. Ko, L.J., and Prives, C. (1996). p53: Puzzle and paradigm. Genes Dev. 10:1054-1072.
3. Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
4. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A. Jr., and Butel, J.S. (1992). Bradley Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
5. Lowe, S.W., and Lin, A.W. (2000). Apoptosis in cancer. Carcinogenesis 21:485-495.
6. Spitz, F.R., Nguyen, D., Skibber, J.M., Cusack, J., Roth, J.A., and Cristiano, R.J. (1996). In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 16:3415-3422.
7. Spitz, F.R., Nguyen, D., Skibber, J.M., Meyn, R.E., Cristiano, R.J., and Roth, J.A. (1996). Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res. 2:1665-1671.
8. Badie, B., Kramar, M.H., Lau, R., Boothman, D.A., Economou, J.S., and Black, K.L. (1998). Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J. Neurooncol. 37:217-222.
9. Foster, B.A., Coffey, H.A., Morin, M.J., and Rastinejad, F. (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510.
10. Swisher, S.G., Roth, J.A., Nemunaitis, J., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Connors, D.G., El-Naggar, A.K., Fossella, F., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, J.S., Mack, M., Merritt, J.A., Nguyen, D.M., Nesbitt, J.C., Perez-Soler, R., Pisters, K.M., Putnam, J.B. Jr., Richli, W.R., Savin, M., Schrump, D.S., Shin, D.M., Shulkin, A., Walsh, G.L., Wait, J., Weill, D., and Waugh, M.K. (1999). Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91:763-771.
11. Komarova, E.A., and Gudkov, A.V. (1998). Could p53 be a target for therapeutic suppression? Semin. Cancer Biol. 8:389-400.
12. Botchkarev, V.A., Komarova, E.A., Siebenhaar, F., Botchkareva, N.V., Komarov, P.G., Gilchrest, B.A., and Gudkov, A.V. p53 is essential for the chemotherapy-induced hair loss. Cancer Res. 60:5002-5006.
13. Komarov, P.G., Komarova, E.A., Kondratov, R.V., Christov-Tselkov, K., Coon, J.S., Chernov, M.V., and Gudkov, A.V. (1999). A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285:1733-1737.
14. Böttger, A., Böttger, V., Sparks, A., Liu, W.L., Howard, S.R, and Lane, D.P. (1997). Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:860-869.
15. Hupp, T.R., Sparks, A., and Lane, D.P. (1995). Small peptides activate the latent sequence- specific DNA binding function of p53. Cell 83:237-245.
16. Selivanova, G., Iotsova, V., Okan, I., Fritsche,M., Ström, M., Groner, B., Grafström, R.C., and Wiman, K.G. (1997). Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3:632-638.
17. Ossovskaya, V.S., Mazo, I.A., Chernov, M.V., Chernova, O.B., Strezoska, Z., Kondratov, R., Stark, G.R., Chumakov, P.M., and Gudkov, A.V. (1996). Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc. Natl. Acad. Sci. U.S.A. 93:10309-10314.
18. Roninson, I.B., Gudkov, A.V., Holzmayer, T.A., Kirschling, D.J., Kazarov, A.R., Zelnick, C.R., Mazo, I.A., Axenovich, S., and Thimmapaya, R. (1995). Genetic suppressor elements: New tools for molecular oncology-thirteenth Cornelius P. Rhoads Memorial Award Lecture. Cancer Res. 55:4023-4028.
19. Prochiantz, A. (1996). Getting hydrophilic compounds into cells: Lessons from homeopeptides. Curr. Opin. Neurobiol. 6:629-634.
20. Derossi, D., Chassaing, G., and Prochiantz, A. (1998). Trojan peptides: The penetratin system for intracellular delivery. Trends Cell. Biol. 8:84-87.
21. Perez, F., Joliot, A., Bloch-Gallego, P., Zahraoui, A., Triller, A., and Prochiantz, A. (1992). Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J. Cell Sci. 102:717-722.
22. Miller, A.D., and Rosman, G.J. (1989). Improved retroviral vectors for gene transfer and expression. Biotechniques. 7:980-986.
23. Prasolov, V.S., and Chumakov, P.M. (2000). Antisense RNA p53 inhibits proliferation of normal and transformed cells. Mol. Biol. (Mosk.) 22:1371-1380.
24. Harvey, D.M., and Levine, A.J. (1991). p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5:2375-2385.
25. Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U.S.A. 90:8392-8396.
26. Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
27. Komarova, E.A., Chernov, M.V., Franks, R., Wang, K., Armin, G., Zelnick, C.R., Chin, D.M., Bacus, S.S., Stark, G.R., and Gudkov, A.V. (1997). Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16:1391-1400.
28. Hogan, B., Beddington, R., Constantini, F., and Lacy, E. (1994) Staining for β-galactosidase (lacZ) activity. In Manipulating with the Mouse Embryo. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New york, pp. 373-375.
29. Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., and DeClerq, E. (1988). Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Meth. 20:309-321.
30. Garkavtsev, I., Grigorian, I.A., Ossovskaya, V.S., Chernov, M.V., Chumakov, P.M., and Gudkov, A.V. (1998). The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature. 391:295-298.